JP2016538885A5 - - Google Patents

Download PDF

Info

Publication number
JP2016538885A5
JP2016538885A5 JP2016554828A JP2016554828A JP2016538885A5 JP 2016538885 A5 JP2016538885 A5 JP 2016538885A5 JP 2016554828 A JP2016554828 A JP 2016554828A JP 2016554828 A JP2016554828 A JP 2016554828A JP 2016538885 A5 JP2016538885 A5 JP 2016538885A5
Authority
JP
Japan
Prior art keywords
composition
raav
vector
seq
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016554828A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016538885A (ja
JP6649265B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/067415 external-priority patent/WO2015081101A1/en
Publication of JP2016538885A publication Critical patent/JP2016538885A/ja
Publication of JP2016538885A5 publication Critical patent/JP2016538885A5/ja
Application granted granted Critical
Publication of JP6649265B2 publication Critical patent/JP6649265B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016554828A 2013-11-26 2014-11-25 糖原病の処置のためのアデノ随伴ウイルスベクター Active JP6649265B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361908861P 2013-11-26 2013-11-26
US61/908,861 2013-11-26
PCT/US2014/067415 WO2015081101A1 (en) 2013-11-26 2014-11-25 Adeno-associated virus vectors for treatment of glycogen storage disease

Publications (3)

Publication Number Publication Date
JP2016538885A JP2016538885A (ja) 2016-12-15
JP2016538885A5 true JP2016538885A5 (enExample) 2017-11-24
JP6649265B2 JP6649265B2 (ja) 2020-02-19

Family

ID=52101617

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016554828A Active JP6649265B2 (ja) 2013-11-26 2014-11-25 糖原病の処置のためのアデノ随伴ウイルスベクター

Country Status (10)

Country Link
US (3) US9644216B2 (enExample)
EP (2) EP3074510B1 (enExample)
JP (1) JP6649265B2 (enExample)
CN (1) CN105934515B (enExample)
AU (1) AU2014354839B2 (enExample)
CA (1) CA2930872C (enExample)
ES (1) ES2690643T3 (enExample)
IL (1) IL245659B (enExample)
MX (1) MX375360B (enExample)
WO (1) WO2015081101A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015191508A1 (en) 2014-06-09 2015-12-17 Voyager Therapeutics, Inc. Chimeric capsids
CN112553229A (zh) 2014-11-05 2021-03-26 沃雅戈治疗公司 用于治疗帕金森病的aadc多核苷酸
MX2017006217A (es) 2014-11-14 2018-05-02 Voyager Therapeutics Inc Polinucleotidos moduladores.
RU2020108189A (ru) 2014-11-14 2020-03-11 Вояджер Терапьютикс, Инк. Композиции и способы лечения бокового амиотрофического склероза (als)
EP3230441A4 (en) 2014-12-12 2018-10-03 Voyager Therapeutics, Inc. Compositions and methods for the production of scaav
US10415044B2 (en) 2014-12-23 2019-09-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adeno-associated virus vectors encoding modified G6PC and uses thereof
WO2017077386A1 (en) * 2015-11-06 2017-05-11 Crispr Therapeutics Ag Materials and methods for treatment of glycogen storage disease type 1a
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
BR112018073472A2 (pt) 2016-05-18 2019-08-27 Voyager Therapeutics, Inc. composições e métodos de tratamento da doença de huntington
AU2017267665C1 (en) 2016-05-18 2023-10-05 Voyager Therapeutics, Inc. Modulatory polynucleotides
WO2018044933A1 (en) 2016-08-30 2018-03-08 The Regents Of The University Of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
WO2018140946A1 (en) * 2017-01-30 2018-08-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant virus vectors for the treatment of glycogen storage disease
CN110536964A (zh) * 2017-03-10 2019-12-03 国立研究开发法人国立成育医疗研究中心 反义寡核苷酸和糖原贮积病Ia型预防或治疗用组合物
CA3061652A1 (en) 2017-05-05 2018-11-08 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
CN111108198A (zh) 2017-05-05 2020-05-05 沃雅戈治疗公司 治疗亨廷顿病的组合物和方法
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
CN111132626B (zh) 2017-07-17 2024-01-30 沃雅戈治疗公司 轨迹阵列引导系统
AU2018338728B2 (en) 2017-09-29 2025-01-02 Centre National De La Recherche Scientifique (Cnrs) Rescue of central and peripheral neurological phenotype of Friedreich's Ataxia by intravenous delivery
CN111479924B (zh) 2017-10-16 2024-06-14 沃雅戈治疗公司 肌萎缩性侧索硬化症(als)的治疗
US20200237799A1 (en) 2017-10-16 2020-07-30 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
CN111511915A (zh) 2018-03-09 2020-08-07 第一三共株式会社 糖原病Ia型治疗药
AU2019268330A1 (en) 2018-05-15 2020-11-26 Voyager Therapeutics, Inc. Compositions and methods for the treatment of Parkinson's disease
CA3100213A1 (en) * 2018-05-16 2019-11-21 Spark Therapeutics, Inc. Codon-optimized acid .alpha.-glucosidase expression cassettes and methods of using same
JP7550057B2 (ja) 2018-06-28 2024-09-12 クリスパー セラピューティクス アーゲー ドナーポリヌクレオチドの挿入によるゲノム編集のための組成物および方法
MX2021003015A (es) * 2018-09-13 2021-07-15 Modernatx Inc Polinucleotidos que codifican glucosa-6-fosfatasa para el tratamiento de la glucogenosis.
EP3856762A1 (en) 2018-09-28 2021-08-04 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
US20220026414A1 (en) * 2018-12-12 2022-01-27 Merck Sharp & Dohme Corp. Cell-based bioidentity test for insulin
PT3898981T (pt) 2018-12-18 2023-12-28 Ultragenyx Pharmaceutical Inc Métodos e composições para tratar doenças de armazenamento de glicogénio
EP3913060A1 (en) * 2020-05-22 2021-11-24 Genethon Vectors encoding a glucose-6-phosphatase (g6pase-a) for gene therapy
CN111972355A (zh) * 2020-08-31 2020-11-24 中国医学科学院北京协和医院 GSDIa型糖原累积症小鼠模型及其构建方法
KR102398032B1 (ko) * 2020-09-22 2022-05-19 비피진 주식회사 암 치료를 위한 5''-뉴클레오티다아제 변이체
US20250222134A1 (en) * 2021-10-19 2025-07-10 University Of Connecticut Compositions and methods for the treatment of glycogen storage disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759050B1 (en) 1998-12-03 2004-07-06 Avigen, Inc. Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith
ES2521682T3 (es) 2003-05-21 2014-11-13 Genzyme Corporation Procedimientos para producir preparaciones de viriones de AAV recombinantes sustancialmente exentas de cápsidas vacías
AU2009209408B2 (en) 2008-01-29 2015-06-11 Beacon Therapeutics Limited Recombinant virus production using mammalian cells in suspension
US20120093775A1 (en) * 2009-03-27 2012-04-19 Proyecto De Biomedicina Cima, S.L. Methods and compositions for the treatment of cirrhosis and liver fibrosis
US8679837B2 (en) 2009-04-02 2014-03-25 University Of Florida Research Foundation, Inc. Inducible system for highly efficient production of recombinant Adeno-associated virus (rAAV) vectors
WO2011094198A1 (en) 2010-01-28 2011-08-04 The Children's Hospital Of Philadelphia Research Institute, Abramson Research Center A scalable manufacturing platform for viral vector purification and viral vectors so purified for use in gene therapy

Similar Documents

Publication Publication Date Title
JP2016538885A5 (enExample)
JP2018501791A5 (enExample)
JP2014512171A5 (enExample)
JP2018520997A5 (enExample)
JP2019522461A5 (enExample)
JP2016537341A5 (enExample)
JP2015513897A5 (enExample)
CL2019002280A1 (es) Vectores virales, adenovirales y composiciones a base de una secuencia de ornitina transcarbamilasa humana (hotch) modificada genéticamente y su uso en el tratamiento de deficiencia de la otc. (divisional solicitud 201602235)
JP2020518276A5 (enExample)
JP2019521139A5 (enExample)
JP2019530462A5 (enExample)
JP2017512767A5 (enExample)
JP2015096557A5 (enExample)
EP4378487A3 (en) Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues
RU2016123086A (ru) Способы и композиции для лечения болезни хантингтона
JP2020514286A5 (enExample)
JP2012136541A5 (enExample)
JP2016506416A5 (enExample)
JP2014523878A5 (enExample)
JP2019513393A5 (enExample)
JP2014503206A5 (enExample)
JP2018532428A5 (enExample)
JP2018537984A5 (enExample)
JP2017538401A5 (enExample)
JP2016539946A5 (enExample)